亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688176 亚虹医药

午间休市 07-18 11:29:30

{"stockData":{"symbol":"688176","market":"SH","secType":"STK","nameCN":"亚虹医药","latestPrice":5.13,"timestamp":1721273370000,"preClose":5.2,"halted":0,"volume":2243296,"delay":0,"floatShares":371000000,"shares":570000000,"eps":-0.7375,"marketStatus":"午间休市","marketStatusCode":3,"change":-0.07,"latestTime":"07-18 11:29:30","open":5.18,"high":5.2,"low":5.11,"amount":11533700,"amplitude":0.0173,"askPrice":5.14,"askSize":7,"bidPrice":5.13,"bidSize":92,"shortable":0,"etf":0,"ttmEps":-0.7375,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721278800000},"adr":0,"adjPreClose":5.2,"symbolType":"stock_kcb","openAndCloseTimeList":[[1721266200000,1721273400000],[1721278800000,1721286000000]],"highLimit":5.72,"lowLimit":4.68,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":570000000,"pbRate":1.29,"roa":"--","roe":"--","epsLYR":-0.7,"committee":0.400689,"marketValue":2924000000,"floatMarketCap":1906000000,"peRate":-6.955932,"changeRate":-0.0135,"turnoverRate":0.006,"status":1},"requestUrl":"/m/hq/s/688176","defaultTab":"news","newsList":[{"id":"2448668483","title":"亚虹医药董事杨明远增持0.13万股，成交均价5.30元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448668483","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448668483?lang=zh_cn&edition=full","pubTime":"2024-07-03 21:04","pubTimestamp":1720011841,"startTime":"0","endTime":"0","summary":"上交所公开信息显示，7月2日，亚虹医药董事、高级管理人员杨明远在二级市场买卖公司股票，增持股数0.13万股，成交均价5.30元，变动金额0.69万元，变动后持股数为3.58万股。近一个月来，亚虹医药共出现2次高管增持，增持总数12.30万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407032132249efc1c28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407032132249efc1c28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2448530101","title":"亚虹医药：7月2日高管杨明远增持股份合计1300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448530101","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448530101?lang=zh_cn&edition=full","pubTime":"2024-07-03 20:01","pubTimestamp":1720008075,"startTime":"0","endTime":"0","summary":"证券之星消息，根据7月3日市场公开信息、上市公司公告及交易所披露数据整理，亚虹医药最新董监高及相关人员股份变动情况：2024年7月2日公司董事,高级管理人员杨明远共增持公司股份1300.0股，占公司总股本为0.0002%。亚虹医药近半年内的董监高及核心技术人员增减持详情如下：亚虹医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出60.09万，融资余额减少；融券净流入0.0，融券余额增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070300041446.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2448103821","title":"亚虹医药：已通过集中竞价交易方式回购股份达到总股本1.0685%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448103821","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448103821?lang=zh_cn&edition=full","pubTime":"2024-07-03 18:44","pubTimestamp":1720003461,"startTime":"0","endTime":"0","summary":"7月3日消息， 亚虹医药 公告，已通过集中竞价交易方式累计回购股份609.04万股，占公司总股本的比例为1.0685%，回购成交的最高价为人民币6.73元/股，最低价为人民币5.08元/股，支付的资金总额为人民币3619.68万元。该回购股份事项符合相关法律法规的规定及公司的回购股份方案，公司将严格按照相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031850199efb5d71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407031850199efb5d71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2448637591","title":"亚虹医药：累计回购股份357.15万股，占公司总股本比例0.6266%，累计已回购金额2298.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448637591","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448637591?lang=zh_cn&edition=full","pubTime":"2024-07-02 22:36","pubTimestamp":1719931008,"startTime":"0","endTime":"0","summary":"亚虹医药 公告，公司已累计回购股份357.15万股，占公司总股本的比例为0.6266%，回购成交的最高价为人民币6.73元/股，最低价为人民币5.33元/股，支付的资金总额为人民币2298.33万元（不含印花税、交易佣金等交易费用）。公司将严格按照相关规定，在回购期限内根据市场情况择机做出回购决策并予以实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070222501495672641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024070222501495672641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2448412154","title":"亚虹医药：公司控股股东累计增持67.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448412154","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448412154?lang=zh_cn&edition=full","pubTime":"2024-07-02 21:19","pubTimestamp":1719926364,"startTime":"0","endTime":"0","summary":"7月2日消息， 亚虹医药 公告称，公司控股股东、实际控制人、董事长兼总经理PAN KE及部分董事、高级管理人员计划自2024年2月5日起6个月内，通过上海证券交易所系统允许的方式增持公司股份，合计增持金额不低于人民币400万元且不超过人民币800万元。截至2024年7月2日，上述增持主体已通过上海证券交易所以集中竞价交易方式累计增持公司股份67.4万股，占公司总股本的0.1183%，增持金额合计人民币400.05万元。此次增持落幕后，PAN KE先生直接持有公司股份1.3亿股，约占公司总股本22.83%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407022130279566c698&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407022130279566c698&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2448046158","title":"亚虹医药：实际控制人及部分董事、高级管理人员增持约67万股，增持计划实施完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2448046158","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448046158?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:54","pubTimestamp":1719921267,"startTime":"0","endTime":"0","summary":"截至2024年7月2日，增持主体通过上海证券交易所以集中竞价交易方式累计增持公司股份约67万股，占公司总股本的0.1183%，增持金额合计人民币400.05万元，截至目前，增持金额已达到并超过相关增持计划拟增持金额区间下限400万元，相关增持股份计划已实施完毕。截至发稿，亚虹医药市值为30亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021954509ef43e01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021954509ef43e01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2448323461","title":"亚虹医药-U申请一种嘧啶类化合物专利，可用于治疗ATR激酶介导的疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2448323461","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448323461?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:45","pubTimestamp":1719917122,"startTime":"0","endTime":"0","summary":"金融界2024年6月28日消息，天眼查知识产权信息显示，江苏亚虹医药科技股份有限公司申请一项名为“一种嘧啶类化合物及其制备方法和医药用途“，公开号CN202211714390.X，申请日期为2022年12月。专利摘要显示，本发明涉及一种嘧啶类化合物及其制备方法和医药用途。具体地，本发明涉及一种通式（I）所示的化合物、其制备方法、含有其的药物组合物及其作为ATR激酶抑制剂用于治疗ATR激酶介导的疾病的用途。通式（I）中各基团的定义与说明书中相同。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021851289ef3ef4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021851289ef3ef4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2448132345","title":"亚虹医药：累计回购约357万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448132345","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448132345?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:24","pubTimestamp":1719915840,"startTime":"0","endTime":"0","summary":"亚虹医药（SH 688176，收盘价：5.27元）7月2日晚间发布公告称，截至2024年6月30日，公司已累计回购股份约357万股，占公司总股本的比例为0.6266%，回购成交的最高价为人民币6.73元/股，最低价为人民币5.33元/股，支付的资金总额为人民币2298.33万元。2023年1至12月份，亚虹医药的营业收入构成为：医药制造业占比100.0%。截至发稿，亚虹医药市值为30亿元。（文章来源：每日经济新闻）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702184044af902c91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240702184044af902c91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2448139450","title":"亚虹医药(688176.SH)：实控人及财务负责人完成增持 耗资400万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2448139450","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448139450?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:21","pubTimestamp":1719915702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)公告，截至2024年7月2日，公司控股股东、实际控制人、董事长兼总经理PAN KE，董事、董事会秘书兼财务负责人杨明远累计增持公司股份67.40万股，占公司总股本的0.1183%，增持金额合计人民币400.05万元，截至目前，增持金额已达到并超过本次增持计划拟增持金额区间下限400万元，本次增持股份计划已实施完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2448139832","title":"亚虹医药(688176.SH)：相关股东累计增持400.05万元公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2448139832","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448139832?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:10","pubTimestamp":1719915054,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨亚虹医药(688176.SH)公布，截至2024年7月2日，增持主体通过上海证券交易所以集中竞价交易方式累计增持公司股份674,029股，占公司总股本的0.1183%，增持金额合计人民币400.05万元，截至目前，增持金额已达到并超过本次增持计划拟增持金额区间下限400万元，本次增持股份计划已实施完毕。增持主体的名称：公司控股股东、实际控制人、董事长兼总经理PANKE先生，董事、董事会秘书兼财务负责人杨明远先生。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021811019565c715&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021811019565c715&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2448837139","title":"亚虹医药(688176.SH)：已累计回购0.6266%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2448837139","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448837139?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:09","pubTimestamp":1719914976,"startTime":"0","endTime":"0","summary":"格隆汇7月2日丨亚虹医药(688176.SH)公布，截至2024年6月30日，公司已累计回购股份3,571,534股，占公司总股本的比例为0.6266%，回购成交的最高价为人民币6.73元/股，最低价为人民币5.33元/股，支付的资金总额为人民币2,298.33万元（不含印花税、交易佣金等交易费用）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021810019ef3ba71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407021810019ef3ba71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2445027835","title":"亚虹医药(688176.SH)：APL-1202临床试验申请获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2445027835","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445027835?lang=zh_cn&edition=full","pubTime":"2024-06-24 19:05","pubTimestamp":1719227121,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)发布公告，公司收到国家药品监督管理局(NMPA)签发的《药物临床试验批准通知书》，公司 APL-1202 用于治疗自由生活阿米巴(Free-living Amoebae，FLA)感染的临床试验申请获得批准。本次 APL-1202 用于治疗自由生活阿米巴(Free-living Amoebae，FLA)感染的临床试验申请获得NMPA批准事项对公司近期业绩不会产生重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK1576","03347","BK1583","BK1141","BK0239"],"gpt_icon":0},{"id":"2445024392","title":"亚虹医药：APL-1202临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2445024392","media":"证券时报网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445024392?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:34","pubTimestamp":1719225240,"startTime":"0","endTime":"0","summary":"证券时报e公司讯，亚虹医药(688176)6月24日晚间公告，公司收到国家药监局签发的《药物临床试验批准通知书》，公司APL-1202用于治疗自由生活阿米巴（Free-living Amoebae，FLA）感染的临床试验申请获得批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062418351495d23053&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062418351495d23053&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2445761021","title":"亚虹医药：获得《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2445761021","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445761021?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:28","pubTimestamp":1719224921,"startTime":"0","endTime":"0","summary":"每经AI快讯，亚虹医药 6月24日晚间发布公告称，近日，江苏亚虹医药科技股份有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，公司APL-1202用于治疗自由生活阿米巴感染的临床试验申请获得批准。2023年1至12月份，亚虹医药的营业收入构成为：医药制造业占比100.0%。截至发稿，亚虹医药市值为30亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062418285695d22bfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062418285695d22bfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2445204337","title":"亚虹医药-U下跌5.05%，报5.26元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2445204337","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445204337?lang=zh_cn&edition=full","pubTime":"2024-06-24 14:37","pubTimestamp":1719211041,"startTime":"0","endTime":"0","summary":"6月24日，亚虹医药-U盘中下跌5.05%，截至14:37，报5.26元/股，成交2887.15万元，换手率1.45%，总市值29.98亿元。截至3月31日，亚虹医药-U股东户数2.99万，人均流通股1.24万股。2024年1月-3月，亚虹医药-U实现营业收入2431.95万元，同比增长106217.71%；归属净利润-8284.82万元，同比减少31.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062414400195d15986&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062414400195d15986&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2445804330","title":"亚虹医药-U创4月新低 近半年1家券商买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2445804330","media":"智选洞察","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445804330?lang=zh_cn&edition=full","pubTime":"2024-06-24 14:37","pubTimestamp":1719211037,"startTime":"0","endTime":"0","summary":"06月24日，亚虹医药-U股价大幅下跌，截至14点37分，亚虹医药-U下跌5.05%，报5.26元/股，创近4月新低，成交2887万元，换手率1.45%。北向资金方面，亚虹医药-U06月21日获得北向资金增持43.40万股，截至06月21日，北向资金当前共持有亚虹医药-U314.64万股，市值1654万元，持股占流通股比为0.84%。主营业务及业绩亚虹医药-U公司主营业务为创新药物的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240624143744aef63b2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240624143744aef63b2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2444723480","title":"亚虹医药董事杨明远增持1.10万股，成交均价5.46元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444723480","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444723480?lang=zh_cn&edition=full","pubTime":"2024-06-18 20:46","pubTimestamp":1718714805,"startTime":"0","endTime":"0","summary":"上交所公开信息显示，6月17日，亚虹医药董事、高级管理人员杨明远在二级市场买卖公司股票，增持股数1.10万股，成交均价5.46元，变动金额6.01万元，变动后持股数为3.45万股。近一个月来，亚虹医药共出现2次高管增持，增持总数16.00万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061821090095bdc0d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024061821090095bdc0d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688176","BK0239"],"gpt_icon":0},{"id":"2444481964","title":"亚虹医药：6月17日高管杨明远增持股份合计1.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2444481964","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444481964?lang=zh_cn&edition=full","pubTime":"2024-06-18 20:01","pubTimestamp":1718712098,"startTime":"0","endTime":"0","summary":"证券之星消息，根据6月18日市场公开信息、上市公司公告及交易所披露数据整理，亚虹医药最新董监高及相关人员股份变动情况：2024年6月17日公司董事,高级管理人员杨明远共增持公司股份1.1万股，占公司总股本为0.0019%。亚虹医药近半年内的董监高及核心技术人员增减持详情如下：亚虹医药的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流入403.12万，融资余额增加；融券净流入0.0，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406182004199f4a6677&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406182004199f4a6677&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2444267841","title":"这家六年亏损的药企研发进展受关注，有核心产品研发四个月前被终止！","url":"https://stock-news.laohu8.com/highlight/detail?id=2444267841","media":"中国制药网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444267841?lang=zh_cn&edition=full","pubTime":"2024-06-18 09:52","pubTimestamp":1718675561,"startTime":"0","endTime":"0","summary":"针对年报问询函所关注的研发进度等问题，亚虹医药近日进行了回复。亚虹医药核心产品均属于在研状态。具体来看，APL-1706的上市申请于2023年11月获国家药品监督管理局受理，公司正在积极推进其上市审评审批工作，并期望于2025年6月底前获得上市批准。此外，同为亚虹医药核心在研产品的APL-1202对应的临床研究正处在开发阶段。值得一提的是，该产品相关研发于四个月前被终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181029519f4875a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406181029519f4875a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688176"],"gpt_icon":0},{"id":"2444118321","title":"核心产品研发进展低于预期 亚虹医药回复年报问询函","url":"https://stock-news.laohu8.com/highlight/detail?id=2444118321","media":"媒体滚动","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444118321?lang=zh_cn&edition=full","pubTime":"2024-06-18 04:03","pubTimestamp":1718654580,"startTime":"0","endTime":"0","summary":"在此背景下，亚虹医药收到了上交所下发的年报问询函。近日，亚虹医药对年报问询函所关注的营业收入、研发进度、应收账款及销售费用四方面问题进行了逐一回复。值得一提的是，这已是亚虹医药连续第六年亏损。核心产品研发受挫 事实上，作为一家创新药公司，亚虹医药最大看点还在于其研发进展上。年报显示，亚虹医药核心产品均属于在研状态，2023年公司研发投入达3.65亿元，同比增加49.49%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-06-18/doc-inazaucw4120202.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-06-18/doc-inazaucw4120202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688176","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-01-07","address":"江苏省泰州市海陵区药城大道一号(创业路东侧、园南路北侧)的新药创制基地二期D幢大楼1009房间","stockEarnings":[{"period":"1week","weight":0.0236},{"period":"1month","weight":-0.0528},{"period":"3month","weight":-0.0972},{"period":"6month","weight":-0.4091},{"period":"1year","weight":-0.5455},{"period":"ytd","weight":-0.5176}],"companyName":"江苏亚虹医药科技股份有限公司","boardCode":"AI0027","perCapita":"12412股","boardName":"医药制造业","registeredCapital":"57000万元","compareEarnings":[{"period":"1week","weight":0.008},{"period":"1month","weight":-0.0176},{"period":"3month","weight":-0.0362},{"period":"6month","weight":0.0461},{"period":"1year","weight":-0.0735},{"period":"ytd","weight":-0.0041}],"survey":"　　江苏亚虹医药科技股份有限公司的主营业务是泌尿生殖系统（UrogenitalSystem）肿瘤及其它重大疾病领域创新药的研发、生产和销售。公司的主要产品是APL-1702、APL-1202、APL-1501(第二代APL-1202)、APL-1706、APLD-2304、AT-014、AT-020、APL-2302、AT-017、AT-018、AT-021、APL-1401、APL-2301。","serverTime":1721277031815,"listedPrice":22.98,"stockholders":"29929人(较上一季度增加2.11%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚虹医药,688176,亚虹医药股票,亚虹医药股票老虎,亚虹医药股票老虎国际,亚虹医药行情,亚虹医药股票行情,亚虹医药股价,亚虹医药股市,亚虹医药股票价格,亚虹医药股票交易,亚虹医药股票购买,亚虹医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚虹医药(688176)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚虹医药(688176)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}